Broadly neutralizing antibody and uses thereof
AssigneesInternational AIDS Vaccine Initiative, The Scripps Research Institute, Cornell University
InventorsDennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok
Life of this patent
Estimating the term…
Abstract
The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 μg/ml, compositions containing the same and uses thereof.
Claims23
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof, comprising (a) a heavy chain sequence comprising an amino acid sequence encoded by SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, or SEQ ID NO:
- 13 and (b) a light chain sequence comprising an amino acid sequence encoded by SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, or SEQ ID NO:
- 26.
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof, comprising
- (a) the heavy chain CDRs of a heavy chain sequence encoded by SEQ ID NO:
- 1, SEQ ID NO:
- 2, SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:
- 5, SEQ ID NO:
- 6, SEQ ID NO:
- 7, SEQ ID NO:
- 8, SEQ ID NO:
- 9, SEQ ID NO:
- 10, SEQ ID NO:
- 11, SEQ ID NO:
- 12, or SEQ ID NO:
- 13, and
- (b) the light chain CDRs of a light chain sequence encoded by SEQ ID NO:
- 14, SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 17, SEQ ID NO:
- 18, SEQ ID NO:
- 19, SEQ ID NO:
- 20, SEQ ID NO:
- 21, SEQ ID NO:
- 22, SEQ ID NO:
- 23, SEQ ID NO:
- 24, SEQ ID NO:
- 25, or SEQ ID NO:
- 26.
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof comprising
- (a) a heavy chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:1, and
- (b) a light chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:
- 14.
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof comprising
- (a) a heavy chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:1, and
- (b) a light chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:
- 14,
- wherein the antibody interacts with HIV gp120 V1/V2 domain of BG505.
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof comprising
- (a) a heavy chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:1, and
- (b) a light chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:
- 14,
- wherein the antibody has a minimal cross-clade neutralization coverage of 80% on the 106-virus panel shown in FIG. 9.
A non-naturally occurring anti-HIV-1 monoclonal antibody or antigen binding portion thereof comprising
- (a) a heavy chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:
- 1, wherein the heavy chain CDR3 comprises the amino acid sequence of SEQ ID NO:
- 40, and
- (b) a light chain variable region comprising an amino acid sequence with at least 90% identity to the amino acid sequence encoded by SEQ ID NO:
- 14, wherein the light chain CDR3 comprises the amino acid sequence of SEQ ID NO:
- 58,
- wherein the antibody interacts with HIV gp120 V1/V2 domain of BG505, and has a minimal cross-clade neutralization coverage of 80% on the 106-virus panel shown in FIG. 9, and
- wherein a triad of aspartic acid residues at the tip of the heavy chain CDR3 provides an anionic potential to the heavy chain CDR3.
An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NO:
- 40-52.
Dependencies are inferred from the claim text.